Mechanisms regulating cerebral blood flow as therapeutic targets

Current Opinion in Investigational Drugs

Volumn 5, Issue 9, 2004, Pages 952-956

  Pratt, Phillip F ^a   Medhora, Meetha ^a   Harder, David R ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Autoregulation; Functional hyperemia; Gene therapy

Indexed keywords

CYTOCHROME P450;

ANIMAL; BRAIN; BRAIN ARTERY; BRAIN CIRCULATION; CEREBROVASCULAR DISEASE; DRUG EFFECT; ENZYMOLOGY; HUMAN; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; VASCULARIZATION;

ANIMALS; BRAIN; CEREBRAL ARTERIES; CEREBROVASCULAR CIRCULATION; CEREBROVASCULAR DISORDERS; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS;

EID: 13244257651     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Harder DR: Pressure-dependent membrane depolarization in cat middle cerebral artery. Circ Res (1984) 55(2):197-202.
2. Roman RJ: P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev (2002) 82(1):131-185.
3. Ignarro LJ: Nitric oxide as a unique signaling molecule in the vascular system: A historical overview. J Physiol Pharmacol (2002) 53(4Pt1):503-514.
4. Volpe M, Cosentino F: Abnormalities of endothelial function in the pathogenesis of stroke: The importance of endothelin. J Cardiovasc Pharmacol (2000) 35(4 Suppl 2):S45-S48.
5. Ergul A: Endothelin-1 and endothelin receptor antagonists as potential cardiovascular therapeutic agents. Pharmacotherapy (2002) 22(1):54-65.
6. 2+ current. J Physiol (1998) 507(3):771-781.
7. Gebremedhin D, Lange AR, Lowry TF, Taheri MR, Birks EK, Hudetz AG, Narayanan J, Falck JR, Okamoto H, Roman RJ, Nithipatikom K et al: Production of 20-HETE and its role in autoregulation of cerebral blood flow. Circ Res (2000) 87(1):60-65.
8. Capdevila JH, Falck JR, Harris RC: Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase. J Lipid Res (2000) 41(2):163-181.
9. Lange A, Gebremedhin D, Narayanan J, Harder D: 20- Hydroxyeicosatetraenoic acid-induced vasoconstriction and inhibition of potassium current in cerebral vascular smooth muscle is dependent on activation of protein kinase C. J Biol Chem (1997) 272(43):27345-27352.
10. + channels in rat hippocampal astrocytes. J Neurosci (2003) 23(5):1678-1687.
11. Alkayed NJ, Narayanan J, Gebremedhin D, Medhora M, Roman RJ, Harder DR: Molecular characterization of an arachidonic acid epoxygenase in rat brain astrocytes. Stroke (1996) 27(5):971-979.
12. Harder DR, Zhang C, Gebremedhin D: Astrocytes function in matching blood flow to metabolic activity. News Physiol Sci (2002) 17:27-31.
13. Gebremedhin D, Ma YH, Falck JR, Roman RJ, VanRollins M, Harder DR: Mechanism of action of cerebral epoxyeicosatrienoic acids on cerebral arterial smooth muscle. Am J Physiol (1992) 263(2Pt 2):H519-H525.
14. Campbell WB, Gebremedhin D, Pratt PF, Harder DR: Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res (1996) 78(3):415-423.
15. Ming Y, Cambj-Sapunar L, Kehl F, Maier KG, Takeuchi K, Miyata N, Ishimoto T, Reddy LM, Falck JR, Gebremedhin D, Roman RJ: Effects of a 20-HETE antagonist and agonists on cerebral vascular tone. Eur J Pharmacol (2004): in press.
16. Miyata N, Taniguchi K, Seki T, Ishimoto T, Sato-Watanabe M, Yasuda Y, Doi M, Kametani S, Tomishima Y, Ueki T, Sato M, Kameo K: HET0016, a potent and selective inhibitor of 20-HETE synthesizing enzyme. Br J Pharmacol (2001) 133(3):325-329.
17. Harder DR, Alkayed NJ, Lange AR, Gebremedhin D, Roman RJ: Functional hyperemia in the brain: Hypothesis for astrocyte-derived vasodilator metabolites. Stroke (1998) 29(1):229-234.
18. Bhardwaj A, Northington FJ, Carhuapoma JR, Falck JR, Harder DR, Traystman RJ, Koehler RC: P-450 epoxygenase and NO synthase inhibitors reduce cerebral blood flow response to N-methyl-D-aspartate. Am J Physiol Heart Circ Physiol (2000) 279(4):H1616-H1624.
19. Gauthier KM, Deeter C, Krishna UM, Reddy YK, Bondlela M, Falck JR, Campbell WB: 14,15-Epoxyeicosa-5(Z)-enoic acid: A selective epoxyeicosatrienoic acid antagonist that inhibits endothelium-dependent hyperpolarization and relaxation in coronary arteries. Circ Res (2002) 90(9):1028-1036.
20. Gauthier KM, Jagadeesh SG, Falck JR, Campbell WB: 14,15-Epoxyeicosa- 5(Z)-enoic-mSI: A 14,15- and 5,6-EET antagonist in bovine coronary arteries. Hypertension (2003) 42(4):555-561.
21. Fisslthaler B, Popp R, Kiss L, Potente M, Harder DR, Fleming I, Busse R: Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature (1999) 401 (6752):493-497.
22. Fleming I, Michaelis UR, Bredenkotter D, Fisslthaler B, Dehghani F, Brandes RP, Busse R: Endothelium-derived hyperpolarizing factor synthase (Cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. Circ Res (2001) 88(1):44-51.
23. Graham-Lorence S, Truan G, Peterson JA, Falck JR, Wei S, Helvig C, Capdevila JH: An active site substitution, F87V, converts cytochrome P450 BM-3 into a regio- and stereoselective (14S,15R)-arachidonic acid epoxygenase. J Biol Chem (1997) 272(2):1127-1135.
24. Muhonen MG, Ooboshi H, Welsh MJ, Davidson BL, Heistad DD: Gene transfer to cerebral blood vessels after subarachnoid hemorrhage. Stroke (1997) 28(4):822-828.
25. Medhora MM, Okamoto H, Narayanan J, Zhang C, Niu X, Taheri MR, Kraemer R, Capdevila J, Harder D: Expression of recombinant cytochrome P450 epoxygenase in rat brain. In: EDHF. Vanhoutte PM (Ed), Taylor & Francis, London, UK (2001):228-238.
26. Munzenmaier DH, Harder DR: Cerebral microvascular endothelial cell tube formation: Role of astrocytic epoxyeicosatrienoic acid release. Am J Physiol Heart Circ Physiol (2000) 278(4):H1163-H1167.
27. Zhang C, Harder DR: Cerebral capillary endothelial cell mitogenesis and morphogenesis induced by astrocytic epoxyeicosatrienoic acid. Stroke (2002) 33(12):2957-2964.
28. Alkayed NJ, Goyagi T, Joh HD, Klaus J, Harder DR, Traystman RJ, Hurn PD: Neuroprotection and P450 2C11 upregulation after experimental transient ischemic attack. Stroke (2002) 33(6):1677-1684.
29. αs mediates induction of tissue-type plasminogen activator gene transcription by epoxyeicosatrienoic acids. J Biol Chem (2001) 276(19):15983-15989.
30. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, Zeldin DC, Liao JK: Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science (1999) 285(5431):1276-1279.
31. Yang B, Graham L, Dikalov S, Mason RP, Falck JR, Liao JK, Zeldin DC: Overexpression of cytochrome P450 CYP2J2 protects against hypoxia-reoxygenation injury in cultured bovine aortic endothelial cells. Mol Pharmacol (2001) 60(2):310-320.
32. Fitzpatrick FA, Ennis MD, Baze ME, Wynalda MA, McGee JE, Liggett WF: Inhibition of cyclooxygenase activity and platelet aggregation by epoxyeicosatrienoic acids. Influence of stereochemistry. J Biol Chem (1986) 261(32):15334-15338.
33. Bylund J, Zhang C, Harder DR: Identification of a novel cytochrome P450, CYP4X1, with unique localization specific to the brain. Biochem Biophys Res Commun (2002) 296(3):677-684.
34. Zou AP, Ma YH, Sui ZH, Ortiz de Montellano PR, Clark JE, Masters BS, Roman RJ: Effects of 17-octadecynoic acid, a suicide-substrate inhibitor of cytochrome P450 fatty acid ω-hydroxylase, on renal function in rats. J Pharmacol Exp Ther (1994) 268(1):474-481.